EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Changing the treatment paradigm in beta thalassemia

Katya Sapunarova iD

Folia Medica · 30.04.2026 · 68 (2)

DOI: 10.3897/folmed.68.e180627 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Folia Medica, online erschienen am 30.04.2026. Verfasst von Katya Sapunarova. Beteiligte Einrichtung: First Department of Internal Medicine, Division of Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria. Hauptthemen laut MEDLINE: beta-Thalassemia, Genetic Therapy. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beta-thalassemia is a hereditary disease that affects the synthesis of β-globin, resulting in ineffective erythropoiesis, chronic anemia, and iron overload. Although the traditional treatment approach, which includes hypertransfusion and chelation therapy, has increased patient survival, it does not address the underlying disease mechanisms. Improving erythroid maturation, increasing fetal hemoglobin synthesis, lowering iron burden, and modifying the disease’s genetic background are the goals that have resulted in the development of several therapeutic classes and treatment options. Erythroid maturation modifiers have been shown to significantly reduce transfusion requirements in patients with beta-thalassemia, and inducers of fetal hemoglobin and hepcidin agonists show promise in controlling ineffective erythropoiesis and secondary iron overload. Gene therapy using lentiviral vectors or CRISPR/Cas9 genome editing has the potential to provide a significant proportion of patients with long-term transfusion independence. These therapeutic advances could significantly improve the quality of life and long-term survival of patients with beta-thalassemia. However, long-term studies are still needed to establish their safety profiles, refine patient selection criteria, and ensure greater access to these innovative treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaGenetic TherapyHumansGene Therapy AgentsFetal HemoglobinErythropoiesisBlood TransfusionImmunoglobulin Fc FragmentsIron OverloadRecombinant Fusion ProteinsActivin Receptors, Type II

Stichwörter der Autor:innen

hemoglobin F synthesis inducers hepcidine modifiers genome editing lentiviral g…

Substanzen

Fetal HemoglobinluspaterceptImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsActivin Receptors, Type II

Autor:innen und Institutionen

  • First Department of Internal Medicine, Division of Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria.

ORCID-Profile: Katya Sapunarova

Zitieren

APA

Sapunarova, K. (2026). Changing the treatment paradigm in beta thalassemia. Folia Medica, 68(2). https://doi.org/10.3897/folmed.68.e180627

Vancouver

Sapunarova K. Changing the treatment paradigm in beta thalassemia. Folia Medica. 2026;68(2). doi:10.3897/folmed.68.e180627

BibTeX
@article{Sapunarova2026,
  author = {Sapunarova, Katya},
  title = {Changing the treatment paradigm in beta thalassemia},
  journal = {Folia Medica},
  year = {2026},
  volume = {68},
  number = {2},
  doi = {10.3897/folmed.68.e180627}
}
Kostenlos starten →